You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Researchers will use the company's Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
The firm has not published validation studies for the test, but new data last week has provided more support for the methylation-based method at its heart.
Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.
About £3.7 million ($4.9 million) of proceeds from the placement would go toward the acquisition, while remaining funds will support assay development validation, and working capital.
The Target Selector technology is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
BUPA Global and other private health insurers have approved reimbursement for OncoDNA's test, which is intended to provide a complete genetic profile of a patient's tumor.
The firm plans to launch its first test from the lab, a mRNA-based noninvasive confirmatory lung diagnostic, by the end of this year.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The firm is approaching launch of its lung cancer test with new sales hires planned, but saw its Q2 net loss miss the consensus Wall Street estimate.
The liquid biopsy firm ran 1,405 tests in the second quarter and made progress on collecting payment from third-party health plans.
The subsidiary of Sysmex is evaluating two liquid biopsy technologies for their abilities to monitor patient response to chemotherapy in breast cancer patients.
The tubes enable noninvasive collection and preservation of biomarkers, such as circulating or total nucleic acids, and protein and cellular biomarkers.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
Today's agreement, which covers the UK, follows distribution deals OncoDNA signed earlier this month covering Morocco and Belarus.
The funds will support a variety of business activities including diagnostic test development and the advance of new methods for tissue-specific exosome isolation.
Diagnostics firm BioHisto Maroc will market and distribute the firm's tissue-based and liquid biopsy sequencing services to oncologists and their patients.
The company's validation studies demonstrate that the assay has a 99 percent negative predictive value, which it believes will persuade physicians of its value.
The company has contracted IPS Genomix to distribute the SelectMDx test in Lebanon, Egypt, the UAE, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan.